# A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

> **NCT04268498** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Miami** · enrollment: 310 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide
- **DRUG:** Acetaminophen
- **DRUG:** Diphenhydramine
- **DRUG:** Montelukast
- **DRUG:** Carfilzomib
- **DRUG:** Daratumumab
- **BIOLOGICAL:** Autologous Stem Cell Transplant (ASCT)

## Key facts

- **NCT ID:** NCT04268498
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-11
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04268498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04268498, "A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04268498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*